Who we are...

The Medical Advisory Group (MAG) is an ad hoc committee of experts charged to examine issues related to the use of aducanumab (Aduhelm) by persons with Down syndrome. The MAG was organized following the FDA's July 7, 2021 approval of the pharmaceutical firm Biogen's medication, aducanumab, for the treatment of Alzheimer's disease.

The ad hoc committee functions under the Clinical Health Care Committee of the NTG, chaired by Seth Keller, MD and Kathryn Service, NPN-BC. 

 

Members of the Advisory Group are drawn from experts across the United States (and other countries) whose work and research with persons with Down syndrome affected by dementia and touches on the many facets of early detection and diagnosis, and interventions, treatments, and health management.  Members are also drawn from health policy, providers, and engaged family members, whose concerns are social care and applicable public policies and support practices.

Documents and publications
An Issues Consensus Statement -- Aducanumab and Persons with Down Syndrome: What Do We Do Now?
    A consensus statement encapsulating the key questions and issues related to the use of
    Aducanumab by persons with Down syndrome

Aduhelm: Rush to Judgement?
  Published version of statement in Exceptional Parent (July 2021)
 
EP version image_edited.jpg